BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service.

Kezar stalls solid tumour trial to focus on autoimmune disease candidate – Pharmaceutical Technology

Enrolment into the Phase I trial investigating Kezar’s solid tumour drug KZR-261 has been halted. Credit: PeopleImages.com – Yuri A via Shutterstock. Clinical stage biopharma

August 14, 2024

Make the Diagnosis: A Blue-Black Facial Nodule — What’s Your Best Guess?

Presentation A 64-year-old postal worker visited his doctor about a lesion that he first noticed on his face 2 months prior. On examination, a shiny,

February 24, 2024

Regular late-life exercise has a beneficial impact on DNA damage and telomere dysfunction

Regular aerobic exercise later in life prevents genomic instability characterized by DNA damage and telomere dysfunction, according to a study from the Department of Internal

April 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.